Similar to CML, gene expression profiling of CD8+ CTLs from AML patients at diagnosis indicate that CTLs in intermediate and high risk AML are less functional than in favorable risk AML and exhibit an exhaustion immune signature (24). The gene discussed is CD8A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.